MAPKAPK2 and neoplasm: (2019) demonstrated that MK2 inhibition following RT significantly reduced cytokine induction and delayed tumor regrowth in a murine model of head and neck squamous cell carcinoma (HNSCC), positioning MK2 as a potential therapeutic target to mitigate radiation-induced metastasis (53).